Search Results - "Pimentel Cáceres, Paola"

Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry by Pérez-Wert, Pablo, Custodio, Ana, Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Lecumberri, Arturo, Cacho Lavin, Diego, Losantos García, Itsaso, Fernández Montes, Ana, Cano, Juana María, Limón, María Luisa, Hernández San Gil, Raquel, Diez, Marc, Vidal Tocino, Rosario, Macías Declara, Ismael, Visa, Laura, Pimentel Cáceres, Paola, Gil Raga, Mireia, Martínez Moreno, Elia, Sauri, Tamara, Martín Richard, Marta, Granja, Mónica, Cerdà, Paula, Gómez González, Lucía, Mérida-García, Antonio, Ruiz Martín, Maribel, Gallego, Javier

“…Background Gastroesophageal adenocarcinoma in young adults (GCYA) counts for 10–15% of diagnoses. Previous studies have mainly focused on surgical outcomes in…”
Get full text

Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study by Valladares-Ayerbes, Manuel, Safont, Maria José, González Flores, Encarnación, García-Alfonso, Pilar, Aranda, Enrique, Muñoz, Ana-Maria López, Falcó Ferrer, Esther, Cirera Nogueras, Luís, Rodríguez-Salas, Nuria, Aparicio, Jorge, Llanos Muñoz, Marta, Pimentel Cáceres, Paola Patricia, Castillo Trujillo, Oscar Alfredo, Vidal Tocino, Rosario, Salgado Fernández, Mercedes, Salud-Salvia, Antonieta, Massuti Sureda, Bartomeu, Garcia-Carbonero, Rocio, Vicente Conesa, Maria Ángeles, Lloansí Vila, Ariadna

“…Purpose RAS ( KRAS / NRAS ) mutational status on a tumor biopsy is mandatory to guide the best treatment in metastatic colorectal cancer (mCRC). Determining…”
Get full text

Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study by López Muñoz, Ana María, González Flores, Encarnación, Carral Maseda, Alberto, Pimentel Cáceres, Paola, Afonso Gómez, Ruth, López López, Carlos, Jimeno Maté, Raquel, Reina Zoilo, Juan José, Castañón López, Carmen, Salgado Fernández, Mercedes, Aparicio Urtasun, Jorge, Asensio Martínez, Elena, Martín Gómez, Teresa

“…To describe the dosing patterns of regorafenib in a real-world population of patients with metastatic colorectal cancer (mCRC) in a routine clinical practice…”
Get full text

Atezolizumab for locally advanced/metastatic urothelial carcinoma within the compassionate use program in Spain: The IMcompass study by Climent Duran, Miguel Angel A., Perez-Gracia, Jose Luis, Arranz Arija, Jose Angel, Alvarez-Fernandez, Carlos, Gomez Mediavilla, Jenifer, Rodriguez, Angel, Vazquez-Estevez, Sergio, Jurado, Jose Miguel, Santander, Carmen, Bonfill, Teresa, Molins Palau, Carmen, Perez Ramirez, Sara, Pimentel Cáceres, Paola, Arnáiz, Pablo, Garate, Zita, Soto, Atenea, Puente, Javier

“…Abstract only 484 Background: Atezolizumab is a monoclonal antibody with proven efficacy in clinical trials for advanced or metastatic urothelial carcinoma…”
Get full text

Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study by Valladares-Ayerbes, Manuel, Garcia-Alfonso, Pilar, Muñoz Luengo, Jorge, Pimentel Caceres, Paola Patricia, Castillo Trujillo, Oscar Alfredo, Vidal-Tocino, Rosario, Llanos, Marta, Llorente Ayala, Beatriz, Limon Miron, Maria Luisa, Salud, Antonieta, Cirera Nogueras, Luis, Garcia-Carbonero, Rocio, Safont, Maria Jose, Falco Ferrer, Esther, Aparicio, Jorge, Vicente Conesa, Maria Angeles, Guillén-Ponce, Carmen, Garcia-Teijido, Paula, Medina Magan, Maria Begoña, Busquier, Isabel, Salgado, Mercedes, Lloansí Vila, Ariadna

“…The serial analysis of cell-free DNA (cfDNA) enables minimally invasive monitoring of tumor evolution, providing continuous genetic information. PERSEIDA was…”
Get full text

Concordance in RAS mutation status between liquid and solid biopsies in subjects with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in first-line treatment in Spain: PERSEIDA study (NCT02792478) by Valladares-Ayerbes, Manuel, Garcia Alfonso, Pilar, Muñoz Luengo, Jorge, Pimentel Cáceres, Paola, Vieitez, Jose María, Cruz-Hernández, Juan J., Llanos, Marta, García Girón, Carlos, Cirera, LLuís, Lloansí Vila, Ariadna

“…Abstract only…”
Get full text

Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry by Viúdez, A., Carmona-Bayonas, A., Gallego, J., Lacalle, A., Hernández, R., Cano, J. M., Macías, I., Custodio, A., Martínez de Castro, E., Sánchez, A., Iglesia, L., Reguera, P., Visa, L., Azkarate, A., Sánchez-Cánovas, M., Mangas, M., Limón, M. L., Martínez-Torrón, A., Asensio, E., Ramchandani, A., Martín-Carnicero, A., Hurtado, A., Cerdà, P., Garrido, M., Sánchez-Bayonas, R., Serrano, R., Jiménez-Fonseca, P.

“…Background The optimal duration of first-line chemotherapy for patients with advanced gastric cancer is unknown. Diverse clinical trials have proposed…”
Get full text

Evolution of IRAS/I Mutations in Cell-Free DNA of Patients with Tissue IRAS/I Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study by Valladares-Ayerbes, Manuel, Garcia-Alfonso, Pilar, Muñoz Luengo, Jorge, Pimentel Caceres, Paola Patricia, Castillo Trujillo, Oscar Alfredo, Vidal-Tocino, Rosario, Llanos, Marta, Llorente Ayala, Beatriz, Limon Miron, Maria Luisa, Salud, Antonieta, Cirera Nogueras, Luis, Garcia-Carbonero, Rocio, Safont, Maria Jose, Falco Ferrer, Esther, Aparicio, Jorge, Vicente Conesa, Maria Angeles, Guillén-Ponce, Carmen, Garcia-Teijido, Paula, Medina Magan, Maria Begoña, Busquier, Isabel, Salgado, Mercedes, Lloansí Vila, Ariadna

“…Cell-free DNA RAS mutation is being increasingly monitored in metastatic colorectal cancer (mCRC) for disease molecular characterization and selecting eligible…”
Get full text